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The role of nitric oxide synthase (NOS) in host defense and clearance of vesicular stomatitis virus (VSV) from the central
nervous system (CNS) was examined. NOS-1, NOS-2, and NOS-3 knockout mice were infected with VSV and were treated
with either IL-12 or medium. IL-12 treatment resulted in substantially decreased VSV titers in wildtype and NOS-3 knockout
mice, but had a marginal effect in the NOS-1 and NOS-2 knockout mice. NOS-1 expression in neurons was associated with
survival from VSV infection. The data indicate that the enzyme activity is local, since NOS-2 expression in microglia and
inflammatory macrophages and NOS-3 expression in astrocytes, endothelial cells, and ependymal cells did not compensate.
© 1999 Academic PressKey Words: viral infection; nitric oxide synthase; interleukin-12; innate immunity; acquired immunity.
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NO is a key component in host defense against a
ariety of pathogens including protozoan parasites,
ungi, bacteria, and viruses (Harris et al., 1995; Karupiah
t al., 1993; Lee et al., 1994; Seguin et al., 1994; Stenger
t al., 1994). It has inhibitory effects on replication of both
NA and RNA viruses (recently reviewed in Reiss and
omatsu, 1998). Recent studies have shown that NO is a
undamental player in physiology (Bredt and Snyder,
994; Nathan, 1992; Nathan and Xie, 1994; Schmidt and
alter, 1994). NO, which is the simplest molecule known
o act as a biological messenger in mammals, was first
dentified as an endothelial cell relaxing factor (Furchgott
nd Zawadzki, 1980; Palmer et al., 1987).
There are three well-characterized isoforms of nitric
xide synthases (NOS). The neuronal form (NOS-1,
NOS, bNOS) is constitutively expressed and posttran-
criptionally regulated; its activity is dependent on Ca21
nd calmodulin. NOS-1 is expressed in neurons in the
NS. The macrophage form (NOS-2, iNOS) is rapidly
nduced by LPS, TNF-a, and IFN-g treatment. It is inde-
endent of Ca21. NOS-2 is a cytosolic dimer under native
onditions (Marletta, 1994). In the CNS, it is expressed in
strocytes and microglia (Galea et al., 1994; Merill et al.,
993; Zielasek et al., 1992). The endothelial cell form
NOS-3, eNOS), is constitutively expressed but posttrans-
ationally regulated, palmytilated, and membrane asso-
1 Present address: Division of Infectious Diseases, Department of
edicine Brigham and Women’s Hospital, Boston, MA 02115.
2 To whom correspondence and reprint requests should be ad-mressed. E-mail: Carol.Reiss@nyu.edu. Fax: 212-995-4015.
389iated. Like NOS-1, it is dependent on Ca21 and calmod-
lin. NOS-3 is expressed in a subset of neurons (Dawson
nd Dawson, 1994), endothelial cells, and astrocytes
Barna et al., 1996).
Interleukin-12 (IL-12) is a heterodimeric cytokine with
5- and 40-kDa subunits (Schoenhaut et al., 1992; Wolf et
l., 1991) which has been shown to mediate a broad
ange of effects on both innate and acquired immunity. It
nduces IFN-g production, regulates T cell proliferation,
timulates NK cell activity, and enhances CD8 CTL re-
ponses (Chan et al., 1991; Chehimi et al., 1993; Koba-
ashi et al., 1989). IL-12 is produced by macrophages, B
ymphocytes (Wolf et al., 1994), dendritic cells, and as-
rocytes (Constantinescu et al., 1996; Stalder et al., 1997).
iral infections rapidly induce IL-12 gene expression
Coutelier et al., 1995; Ireland et al., 1998).
Exogenous IL-12 injection is an effective therapy in
any viral systems (recently reviewed in Komatsu et al.,
998), promoting enhanced recovery from VSV infection
f the CNS (Bi et al., 1995; Komatsu and Reiss, 1997).
owever, neither IFN-g nor TNF-a is required for IL-12
fficacy (Komatsu et al., 1997). We have shown both in
itro and in vivo that NO is a potent antiviral effector
olecule for VSV, reducing yields by 2 log10 (Bi and
eiss, 1995; Komatsu et al., 1996, 1999b).
We carried out this study to determine whether NOS-1,
OS-2, and/or NOS-3 were critical to the host response
o VSV. IL-12 was administered to groups of VSV-infected
57BL/6 (B6) wild-type (WT), NOS-1 2/2, NOS-2 2/2,
nd NOS-3 2/2 mice. The survival of these mice was
bserved over a 2-week period. At various time points,
he viral titers of the brain homogenates were deter-
ined.
0042-6822/99 $30.00
Copyright © 1999 by Academic Press
All rights of reproduction in any form reserved.
M
i
w
n
w
N
c
m
c
f
f
t
m
a
i
w
o
c
h
d
i
2
a
m
s
(
N
a
a
t
I
t
b
t
g
t
m
I
o
N
V
2
a
n
f
s
C
s
I
t
m
(
e
c
s
t
c
c
w
t
W
i
T
a
h
u
N
a
N
a
t
I
C
a
N
n
t
t
W
N
N
N
P
d
B
N
W
390 KOMATSU ET AL.RESULTS
orbidity and mortality: IL-12 treatment resulted in
ncreased survival and more rapid recovery from
eight loss
We have previously shown in vitro that treatment of
euroblastoma cells, astrocytomas, or macrophages
ith IL-12, IFN-g, or TNF-a resulted in upregulation of
OS activity, accompanied by induction in immunohisto-
hemically detectable enzymes (Barna et al., 1996; Ko-
atsu et al., 1996). Therefore, we wanted to examine the
ourse of VSV infection in mice deficient in three iso-
orms of NOS.
IL-12 treatment resulted in an increased survival rate
rom VSV infection in WT mice compared to media-
reated WT mice, as we have previously reported (Ko-
atsu et al., 1996; Komatsu and Reiss, 1997). We have
lso measured the weight changes of mice in the exper-
ments shown, as an indication of morbidity associated
ith infection. The data are consistent with the survival
f the mice (not shown). VSV infection resulted in in-
reased mortality in NOS-1 2/2 mice compared to WT
ost mice, suggesting that NOS-1 is important for host
efense (Table 1). In addition, IL-12 treatment did not
mprove, but rather increased, the mortality of NOS-1
/2. NOS-2 2/2 mice treated with media were margin-
lly more likely to survive than IL-12-treated NOS-2 2/2
ice. NOS-3 2/2 mice responded to IL-12 treatment and
urvived the infection at a rate similar to that of WT
Table 1). This implies that the activity of NO is local, and
OS expression within infected neurons, not adjacent
strocytes or endothelial cells (NOS-3) or in microglia
nd inflammatory monocytes (NOS-2), is the critical de-
TABLE 1
Effect of Deficiency of Distinct NOS Isoforms
on Survival from VSV Encephalitis
% Survival on day 14
postinfection
Haplotype No. trials Media IL-12
T 6 60 6 12.9 91.6 6 8.9
OS-1 2/2 2 48 6 8 36 6 16
OS-2 2/2 2 85 6 15 68 6 7.5
OS-3 2/2 2 55 6 5 90 6 10
Note. Groups of 8–10 mice were infected intranasally with 2 3 105
FU VSV i.n. and were treated either with media or with 200 ng IL-12 ip
aily for a week. Mice were observed for 2 weeks following infection.
oth NOS-1 2/2 1 media and NOS-1 1 IL-12 data vs WT, P , 0.001;
OS-2 2/2 1 IL-12 vs WT P , 0.001; NOS-3 2/2, not different than
T, Kruskal–Wallis test.erminant for modulating viral infection. mL-12 treatment resulted in decreased VSV titers in
he brain homogenates in WT and NOS-3 2/2 mice,
ut not in NOS-1 or NOS-2 knockout mice
Our earlier studies showed a good correlation be-
ween IL-12 treatment and enhanced ability to limit viral
rowth both in vitro and in vivo. The viral titers of mice
reated with IL-12 were lower in WT and NOS-3 2/2
ice than in the same strains treated with media. This
L-12-associated inhibition of viral propagation was not
bserved in NOS-1 2/2 or NOS-2 2/2 mice (Fig. 1).
OS-1 2/2 mice were found to have the highest titers of
SV in homogenates of all the strains tested. Injection of
00 ng of IL-12/mouse per day decreased the VSV titer
bout 100-fold for the WT and NOS-3 2/2 mice. Immu-
ohistochemical staining of VSV Ags on frozen sections
rom brains of other mice confirmed this observation and
howed viral Ag to be limited to more rostral areas of the
NS, consistent with early limitation of viral spread (not
hown).
L-12 treatment induces activation of parenchymal
issue and inflammatory infiltrates
The brain sections from infected WT and knockout
ice were stained for either glial fibrillary acidic protein
GFAP), a marker of activated astrocytes, or Mac-1 Ag
xpressed by microglia and inflammatory mononuclear
ells. The most pronounced astrocytosis and microglio-
is was observed to coincide with VSV Ag1 areas. IL-12
reatment resulted in more numerous and heavily stained
ells, suggesting that astrocytosis and microgliosis oc-
urred in response to cytokine treatment. Similarly, there
as coordinate induction of NOS-1, -2, and -3 in sections;
he knockout mice expressed all but the deleted isoform.
e observed upregulation of NOS-3 in ependymal cells
n WT and NOS-1 2/2 mice which had been infected.
here was no effect on the parenchymal cell activation
ssociated with deficiency in NOS isoforms (not shown).
NK1.1 expressing cells were detected at relatively
igher frequency in the infected media-treated than in
ninfected brains. A profound increase in the number of
K cells was found in the olfactory bulb (OB) and other
reas following IL-12 treatment in WT, NOS-1 2/2, and
OS-3 2/2 sections (Fig. 2). This is consistent with IL-12
ctivating NK cells, which sought the inflammatory site.
T cells were detected very infrequently in media-
reated infected B6 and uninfected B6 mouse brains.
L-12 treatment resulted in the accumulations of CD4 and
D8 expressing T cells in the VSV-infected areas such
s the OB (Fig. 2) and HC (not shown). In both infected
OS-1 2/2 and NOS-3 2/2 hosts, IL-12 treatment did
ot recruit more T lymphocytes to the CNS, in contrast to
he effect of IL-12 in WT infected hosts. This suggests
hat the deficiencies might have altered the chemokineilieu to create a less inflammatory environment.
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391FOR VSV INFECTION NEURONAL NOS IS CRITICALDISCUSSION
These studies demonstrate that IL-12 inhibits VSV
eplication through induction of NOS-1 in neurons in
ivo, but not through induction of NOS-2 in microglia
nd inflammatory mononuclear cells or NOS-3 in as-
rocytes, ependymal, and endothelial cells (Table 1
nd Fig. 1). We have previously shown in vitro that
ytokine treatment of neuroblastoma cells resulted in
2 log10 decrease in viral titers which was inhibitable
y L-NMA treatment, a NOS inhibitor (Komatsu et al.,
996). A similar observation was made in vivo when
he NOS-1 selective inhibitor 7-nitroindazole was used
Komatsu et al., 1996). Our observation using NOS-1
/2 mice is consistent with the previous observa-
ions; that is, mice deficient in NOS-1 were very sus-
eptible to lethal infection and cytokine treatment did
ot improve any outcome parameter.
Interestingly, NOS-3 2/2 mice responded to IL-12 and
ere able to inhibit the viral replication, similar to WT
ice. However, NOS-2 2/2 mice did not respond with
hanges in their antiviral responses. This suggests that
FIG. 1. IL-12 treatment significantly inhibited VSV replication in the C
SV titers in CNS homogenates are shown for days 3, 4, and 6 post
cross-hatched bar), and NOS-3 2/2 mice (stipled bar) were infected
r 200 ng IL-12, on days 0–5 postinfection. All mice were infected intra
roup were sacrificed and the mouse brains were homogenized for de
ut not NOS-1- or NOS-2-deficient mice receiving IL-12 treatment were
y the Student’s t test (P , 0.01). The experiment was done twice.ome NO produced by microglia can diffuse and facili- vate neuronal handling of the virus. We have observed
hat astrocytes express NOS-3 in the olfactory bulb as
arly as day 1 pi (Barna et al., 1996). NOS-3 is also
xpressed and IL-12 enhanced in endothelial and
pendymal cells (not shown). Yet, this NOS-3 expression
nd diffusion of NO from astrocytes to neurons in the
lfactory bulb does not seem to be modulating viral
eplication in NOS-1 2/2 mice. Since virus is present in
he OB neurons, this suggests that the activity of NOS is
ntracellular. We have observed that although NOS-3 is
ot playing a critical role in the VSV replication or host
urvival (Table 1, Fig. 1), it may have a vital role in viral
isease pathogenesis, that is, in the integrity of the
lood–brain barrier (Komatsu et al., 1999a). NOS-2 does
ot appear to be critical in the CNS for elimination of VSV
r for survival.
Most of the previous work on pathogenesis involving
O has been done using pharmacologic inhibition of
OS activity (reviewed in Reiss and Komatsu, 1998).
here is accumulating evidence that NO has an inhibi-
ory effect on a variety of virus infections in vitro and in
OS-3 2/2 and WT mice, but not in NOS-1 2/2 or NOS-2 2/2 mice.
n. WT (solid bar), NOS-1 2/2 mice (hatched bar), NOS-2 2/2 mice
groups of six. Mice were injected ip with either the control medium
with VSV (2 3 105 PFU/10 ml). On day 3.4, or 6 p.i., six mice of each
tion of viral titers on CHO cells. Viral titers of WT and NOS-3-deficient
to be significantly lower than those of the control mice, as determinedNS in N
infectio
twice in
nasally
termina
foundivo (Reiss and Komatsu, 1998); however, this is not
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392 KOMATSU ET AL.niversal. In some systems, activity of NOS-2 has been
hown to be associated with inflammatory pathology, for
nstance Bornavirus disease or HSV-1 pneumonia (Ko-
rowski et al., 1993; Adler et al., 1997). We have not
bserved that in VSV infection.
NO may be influencing several steps in the VSV life
ycle to inhibit viral replication. Although there is a mod-
st inhibition of viral RNA synthesis, there is a profound
ecrease in viral protein accumulation. It may be inacti-
ating host and viral proteins through nitrosylation (Ko-
atsu et al., 1999b). In the Coxsackie virus B3 model, NO
as found to inactivate the viral protease (Saura et al.,
999).
Neurons normally do not express MHC class I and II
ntigens. Thus, the utilization of NO as an antiviral com-
onent may be an essential strategy for activated neu-
ons to retard viral dissemination from infected cells. The
ost may rely on NO and other noncytotoxic effect of
FN-g inducible proteins to clear virus from the CNS
uring the early stages of infection without the cytolytic
ffects of NK and T cells (Bi and Reiss, 1995). It has been
hown that in some cases, NK cells can indirectly restrict
iral replication without lysis of the virus-infected cells by
timulating NO production in macrophages (Karupiah
FIG. 2. T and NK cell infiltration into the olfactory bulb. T and NK cell
/2 (hatched bars), and NOS-3 2/2 (stipled bars) mice were mock-infe
ections of three mouse brains, removed at day 4 pi, were stained for C
he left four sets of bars are T cell determinations (media-treated unin
SV infected). The right four sets of bars are NK cell determinations.nd Harris, 1995). Thus, this type of inhibitory mechanism say furnish what is lacking in acquired immunity for
irus clearance from the CNS (Lin et al., 1997).
IFN-g can inhibit several viral infections in macro-
hages through iNOS induction (Karupiah et al., 1993).
e have also reported that IFN-g can induce NO in
B41A3 cells, which inhibits viral infections (Bi and
eiss, 1995; Komatsu et al., 1996). Considering that NO-
enerating neurons are selectively resistant to NO neu-
otoxicity (Dawson et al., 1991), one more advantage can
e attributed to cytokine-mediated activation of NOS in
eurons in inhibiting viral infections in the CNS rather
han simply just induction of iNOS in neighboring neuro-
lial cells.
Cytokine treatment of NB41A3 results in upregulation
f NOS-1, determined by immunoprecipitating NOS-1
Komatsu et al., 1996). Little is known about the mecha-
ism(s) of IL-12 regulation of type I NOS at present. It is
ossible that IL-12 increases NOS gene expression at
he transcriptional level, or IL-12 increases the quantity of
OS posttranscriptionally by either increasing the half-
ife of NOS mRNA or stabilizing the NOS protein. IFN
egulatory factor (IRF)-1 is required in iNOS induction in
ouse macrophages (Kamijo et al., 1994). Cytokine sig-
al transduction in neurons, however, may or may not be
on were determined by immunohistochemistry. WT (solid bars), NOS-1
VSV-infected and were treated with either media or with IL-12. Sagittal
CD8. Positively stained cells were counted under a light microscope.
media-treated VSV infected; IL-12 treated uninfected; or IL-12 treatedinfiltrati
cted or
D4 and
fected;imilar to that in other types of cells. Two closely linked,
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393FOR VSV INFECTION NEURONAL NOS IS CRITICALut separable, promoters of human type I NOS have
een identified (Xie et al., 1995). However, the human
OS-2 gene is regulated differently than the mouse ho-
olog and is not readily inducible by IFN-g, TNF-a, or
PS (Reiling et al., 1994). There may be other cytokine
esponse elements in the 59 region of the gene, and only
uture investigations including the isolation of the murine
romoter(s) will provide the insights necessary. We are
ctively investigating the IL-12 receptor and its signal
ransduction pathway(s) in neurons.
MATERIALS AND METHODS
iruses
VSV Indiana serotype, San Juan strain, was propa-
ated in Chinese hamster ovary cells and twice purified
sing a sucrose gradient. Viral titers were determined on
onolayers of Chinese hamster ovary cells as previously
escribed (Huneycutt et al., 1993).
xperimental infection of mice
Specific pathogen-free male C57BL/6 B6 WT (Jackson
aboratory, Bar Harbor, ME), NOS-1 2/2, NOS-3 2/2
ice (breeding pairs provided by Dr. Mark Fishman and
r. Paul Huang, MGH; Huang et al., 1993, 1994), and
OS-2 2/2 (breeding pairs were obtained from the
ackson Labs) were used throughout the experiment.
Mice were lightly anesthetized for 1 min in a closed
ontainer containing Halothane (Halocarbon Lab, North
ugusta, SC), followed by intranasal infection with 2 3
05 plaque-forming units (PFU) of VSV in a total volume of
.01 ml administered equally through each nostril, as
reviously described (Bi and Reiss, 1995). NOS-3 KO
ice were found to be much more sensitive to anesthe-
ia than were WT or other KO strains we have tested. Ten
ice in each treatment group were reserved for evalua-
ion of morbidity (weight changes) and mortality (Plakhov
t al., 1995). At each time point, at least 8 mice per
reatment group were given a lethal dose of ketamine
ylazine. Six brains from each group were homogenized
nd frozen for later determination of viral titers, as pre-
iously described (Bi and Reiss, 1995; Forger et al., 1991).
he lower limit of detection of the assay is 100 PFU/ml
omogenate. The other three mice in each group were
erfused transcardially with 20 to 30 ml of normal saline,
nd the whole brains were removed and quick-frozen in
sopentene kept on dry ice before being stored at 270°C
ntil sectioning, as previously described (Bi and Reiss,
995).
rotocol of in vivo treatment of IL-12
Murine rIL-12 was generously provided by Genetics
nstitute (Cambridge, MA). On the day of infection,
roups of mice were injected ip daily with medium alone ir 200 ng of IL-12/mouse; this was continued daily from
to 7 days postinfection.
ells and viruses
Chinese hamster ovary (CHO) cells, obtained from Dr.
lice S. Huang, were maintained as previously described
Huneycutt et al., 1993). Infectious virus was quantified by
laque assay on CHO cell monolayers. Monolayers were
repared by inoculating 20 3 104 cells in 1 ml per well
24-well plate, Nunc) and incubated for 2 days at 37°C.
he medium was removed, 0.1 ml of each dilution of
amples (10-fold serial dilutions) was added to each
ell, in duplicate, and the wells were then incubated for
0 min at 37°C. The medium was removed, 1 ml of the
ixture of equal volumes of 1.8% agar (kept at 45°C) and
3 culture medium (kept at 37°C) was added to each
ell, and the wells were then incubated at 37°C for 24 h.
laques were fixed with 10% formaldehyde for 30 min
nd stained with 0.5% methylene blue.
mmunohistochemical reagents
Most serological reagents used in this study are listed
n Table 2. Biotin-labeled secondary Abs specific for the
pecies of the primary Abs and avidin-biotinylated horse-
adish peroxidase complex were purchased from Vector
aboratories (Burlingame, CA). 3,39-Diaminobenzidine
DAB) and its diluting buffer were obtained from Calbio-
hem Corporation (San Diego, CA).
mmunohistochemical staining
Brains were sectioned (20-mm sections) in the sagittal
rientation using a cryostat; 20–30 serial sections of
ach brain were prepared on subbed slides. In each
taining experiment, brain sections were removed from
he freezer and warmed at room temperature for 10 min
efore being fixed in 10% neutral buffered Formalin for 1
in. Sections were then washed twice in 0.1 M Tris-
uffered saline (TBS, ph 7.6), 10 min each. Endogenous
eroxidase activity was blocked by incubating sections
TABLE 2
Primary Antibodies Used for Immunohistochemistry
Antigen Reagent Isotype Dilution Source
icroglia Anti-Mac-1 Rat 1:25 Pharmingen
strocytes Anti-GFAP Rabbit 1:100 Dako Inc.
D41 T Anti-L3T4 Rat 1:25 Pharmingen
D81 T Anti-Lyt 2.2 Rat Sup. ATCC
OS-2 Anti-iNOS Rabbit 1:50 Transduction Lab
OS-3 Anti-eNOS Rabbit 1:50 Transduction Lab
OS-1 Anti-nNOS Mouse 1:50 Transduction Lab
SV Anti-VSV Sheep 1:200 E. O’Rourke
K NK1.1 Mouse 1:50 Pharmingenn 0.3% H2O2 in 0.1 M TBS for 20 min. Sections were then
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394 KOMATSU ET AL.ashed twice in 0.1 M TBS, and background staining
as blocked by preincubation in 1% bovine serum albu-
in (BSA) (Fisher Scientific, Pittsburgh, PA) in 0.1 M TBS
or 45 min. Sections were then incubated with primary
bs for specific Ags for 1 h at room temperature, except
or VSV staining, which was conducted overnight. Sec-
ions were washed again in 0.1 M TBS twice and then
ncubated in biotinylated secondary Ab (ABC Kit, Vector
aboratories), followed by avidin-biotinylated peroxidase
or another 30 min. Sections were then incubated with
AB in 0.01% H2O2 for 5 min. Dried sections were cov-
rslipped with Permount (Fisher Scientific).
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